Last reviewed · How we verify
Mupirocin Ointment [Treatment]
Mupirocin inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase, preventing bacterial growth and reproduction.
Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, preventing protein synthesis and causing bacteriostatic activity against susceptible bacteria. Used for Impetigo, Infected skin lesions and minor skin infections, Nasal colonization with Staphylococcus aureus (including MRSA).
At a glance
| Generic name | Mupirocin Ointment [Treatment] |
|---|---|
| Also known as | Bactroban ointment, Mupirocin 2% in Polyethylene Glycol (PEG) Ointment |
| Sponsor | US Department of Veterans Affairs |
| Drug class | Topical antibiotic |
| Target | Isoleucyl-tRNA synthetase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Mupirocin is a topical antibiotic that selectively inhibits bacterial isoleucyl-tRNA synthetase, an enzyme essential for bacterial protein synthesis. By blocking this enzyme, mupirocin prevents bacteria from synthesizing proteins necessary for survival and replication. This mechanism is bacteriostatic and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Impetigo
- Secondary bacterial skin infections
- Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA)
Common side effects
- Local skin irritation
- Burning or stinging at application site
- Erythema
- Pruritus
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mupirocin Ointment [Treatment] CI brief — competitive landscape report
- Mupirocin Ointment [Treatment] updates RSS · CI watch RSS
- US Department of Veterans Affairs portfolio CI